
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 10, 2008 (March 5, 2008)

Lifevantage Corporation

(Exact name of registrant as specified in its charter)

Colorado

(State or other jurisdiction
of incorporation)

000-30489

(Commission File Number)

90-0224471

(IRS Employer Identification No.)

6400 South Fiddler's Green Circle, Suite 1970, Greenwood Village, CO 80111

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (720) 488-1711

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 2.02 Results of Operations and Financial Conditions

On March 5, 2008, Lifestage Corporation issued a press release entitled, "Lifestage Corporation Schedules 2nd Quarter FY 2008 Conference Call". The press release is attached as Exhibit 99.1 hereto, which is furnished under Item 2.02 of this report and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act") or the Exchange Act, regardless of any general incorporation language in such filing.

Item 7.01 Regulation FD Disclosure

On March 5, 2008, Lifestage Corporation issued a press release entitled, "Lifestage Corporation Schedules 2nd Quarter FY 2008 Conference Call". The press release is attached as Exhibit 99.1 hereto, which is furnished under Item 7.01 of this report and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing.

David Brown, President and Chief Executive Officer of Lifestage Corporation, will present a business presentation during the 2nd Quarter FY 2008 Conference Call. The business presentation is attached as Exhibit 99.2 hereto, which is furnished under Item 7.01 of this report and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, regardless of any general incorporation language in such filing.

Item 9.01 Exhibits

99.1 Press release, dated March 5, 2008, entitled, "Lifestage Corporation Schedules 2nd Quarter FY 2008 Conference Call".

99.2 Business Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 10, 2008

LIFEVANTAGE CORPORATION

By: /s/ Bradford K. Amman

Bradford K. Amman
Secretary/Treasurer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Document</u>
99.1	Press release, dated March 5, 2008, entitled, "Lifevantage Corporation Schedules 2nd Quarter FY 2008 Conference Call".
99.2	Business Presentation



FOR IMMEDIATE RELEASE

March 5, 2008

NEWS
OTCBB: LFPV

**LIFEVANTAGE CORPORATION SCHEDULES 2ND QUARTER FY 2008
CONFERENCE CALL**

GREENWOOD VILLAGE, Colorado — LifeVantage Corporation (OTCBB: LFPV), formerly Lifeline Therapeutics, Inc., maker of Protandim[®], will hold a conference call on Tuesday, March 11, 2008 at 9:00 a.m. MT (11:00 a.m. ET) to introduce its new CEO David Brown, discuss its second quarter fiscal year 2008 financial and operating results, and remind investors of upcoming warrant expiration dates and repricing opportunities. Mr. Brown's presentation will be available on Monday, March 10, 2008 via the Company's website.

Interested parties may listen to the call by dialing 800-240-2430. A replay of the call also will be available by telephone until March 18, 2008 at 800-405-2236 passcode 11110173#.

About Protandim[®]

Protandim[®] is a unique approach to fighting the effects of cell-damaging free radical molecules which advance the aging process, including many of the diseases of aging. The patented dietary supplement increases the body's natural antioxidant protection by inducing the cells of the body to produce naturally occurring protective antioxidant enzymes, a process which is thousands of times more effective than traditional vitamin-mineral supplements. Free radical damage occurs when a person is subjected to environmental stresses and generally increases with age. Data from a peer-reviewed scientific study in men and women, sponsored by LifeVantage, show that after 30 days of taking Protandim[®], the level of circulating toxins produced by free radicals decreased an average of 40 percent. With continued use, the decrease was maintained at 120 days. For more information, please visit the Protandim[®] product web site at www.protandim.com or contact Jan Strode at (619) 890-4040.

About LifeVantage Corporation

LifeVantage Corporation is a publicly traded (OTCBB: LFPV), science based, natural products company, dedicated to helping people reach their health and wellness goals through science-based solutions to oxidative stress. Founded in 2003 and based in Colorado, LifeVantage develops nutraceutical products, including Protandim, that leverage the company's expertise and that are intended to deliver significant health benefits to consumers. For more information, visit www.protandim.com or contact Jan Strode at (619) 890-4040.

This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company uses the words "anticipate," "believe," "could," "should," "estimate," "expect," "intend," "may," "predict," "project," "plan," "target" and similar terms and phrases, including references to assumptions, to identify forward-looking statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks

and uncertainties include, among others, the risk that government regulators and regulations could adversely affect our business; future laws or regulations may hinder or prohibit the production or sale of our existing product and any future products; unfavorable publicity could materially hurt our business; and the Company's ability to protect our intellectual property rights and the value of our product. These and other risk factors are discussed in greater detail in the Company's Annual Report on Form 10-KSB under the caption "Risk Factors", and in other documents filed the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law. In light of these risks and uncertainties, investors should keep in mind that the results, events or developments disclosed in any forward-looking statement made in this news release may not occur.

###

CONTACTS:

LifeVantage Corporation

Jan Strode, Investor Relations

Telephone: (619) 890-4040


Bradford Amman, Treasurer

Telephone: (720) 488-1711

LIFE VANTAGE

Investor Presentation
March, 2008

www.LifeVantage.com
Trading Symbol on OTCBB: LFVN




Statements in this presentation which are not statements of historical fact are "forward-looking statements" within the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on information available to, and the expectations and assumptions deemed reasonable by Lifeline Therapeutics, Inc. and Lifevantage Corporation (the "Company") at the time this presentation was made. Although the Company believes that the assumptions underlying such statements are reasonable, it can give no assurance that they will be attained. Factors that could cause actual results to differ materially from expectations include the risks detailed under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-KSB, and risks identified in the Company's quarterly reports on Form 10-QSB and in other materials filed by the Company from time to time with the Securities and Exchange Commission.

2007: A Turn-Around Year


- ▶ \$100K Cash Flow Positive in First Six Months of FY 2008
- ▶ Q1/Q2 08: First Quarters of Increasing Cash Flow From Operations since 2005
- ▶ Expenses Drastically Reduced

Convergence of Sales & Operating Expenses*




* In Thousands

** Fiscal Year Ends June 30




2008: A New Direction

- ▶ New CEO and Management Team In Place
- ▶ Strong Product in High Growth Segment
- ▶ Aggressive Pursuit of New Sales Channels



Substantial International Licensing Agreement Announced in February.



Management Team:



- ▶ David Brown, CEO
 - Seasoned Industry Veteran—Hired January '08
 - CEO & President, Metabolife International
 - Transitioned leading dietary supplement company from direct sales to retail channels
 - President, Natural Balance, Inc.
 - Directed expansion from health food channels to mass-market retail
 - Revenue growth of over 300% in 5 year period
 - Expanded sales internationally to 40+ countries

Management Team Additions:

- ▶ **Peter Baloff, Marketing**
 - Authority on health/nutrition marketing
 - Produced over 200 commercials: Princess Cruises, Hallmark, Universal Pictures, Capital Records
 - Natural Products: Jenny Craig, Bally Total Fitness, Natural Balance, Interior Design (Nu-Skin)

- ▶ **Jan Strode, Corporate Communications**
 - Firestone Tire & Rubber: Handled all government affairs during critical tire recall
 - Sanyo Corporation: Managed global PR strategy
 - Hollis-Eden Pharmaceuticals (HEPH): National and International PR & regulatory affairs

AGING progresses **slowly** when we're young...



...because a young body defends itself more **efficiently** by **creating ample amounts of antioxidants** to neutralize most of the free-radicals produced in the body.

As we grow older the AGING process **progresses rapidly**

and we age poorly because our bodies lose the ability to produce enough **antioxidants** to keep up with the amount of **free-radicals** ravaging our cells.



Free radicals are the same deadly molecules that cause **rust...** (O₂)



In a sense, aging is your body's way of rusting from the inside out.




This free-radical damage that causes aging is called **Oxidative Stress**

The Product: Protandim[®]


- ▶ Clinically proven, patented dietary supplement
- ▶ Increases the body's natural antioxidant protection at the cellular level



Oxidative damage caused by free radicals can be **measured** by the amount of toxins they produce. Those toxins are called **TBARS** and **increase with age**.




In a peer reviewed, published, human medical study, the amount of oxidative damage (TBARS) was measured in control subjects of all ages, many of whom were taking antioxidant supplements.



As shown, traditional antioxidant supplements in normal healthy humans do not affect the age-related increase in oxidative damage.

Subjects who take Protandim for 30 days show significant decrease in TBARS



Among control subjects of **all ages**, the acceleration of aging as measured by the amount of oxidative damage (TBARS) has been **reduced** to the level of a 20 year old.

The Market: Over **\$100 Billion** Per Year is Spent Fighting the **Aging** Process.

- ▶ Anti-aging supplements (about \$5 billion)*
- ▶ Anti-aging services and related products (about \$50 billion)**
- ▶ Other cosmetic products such as make-up (about \$50 billion)***
- ▶ Exercise equipment (about \$5 billion)****



*2005, Nutrition Business Journal

** 2007, Business Communications Co.

***2006, Euromonitor International

**** 2007, Sporting Goods Manufacturers Association

Sustaining Competitive Advantage:

Existing & Future Research Ensures Barrier to Entry


- Over 20 Independent Human Clinical and Lab Studies Underway at Leading Institutions Including:

- University of Colorado
- Denver Health Medical Center
- Children's Hospital, Denver
- University of Florida
- University of Kentucky
- University of Michigan
- Louisiana State University

Patent No.: US 7,241,461,
"Compositions for Alleviating
Inflammation and Oxidative
Stress in a Mammal"

Topics Under Investigation:

- Altitude sickness
- Skin cancer
- Photoaging of the skin
- Renal failure
- Osteoarthritis
- HIV/AIDS-associated lipodystrophy
- Pulmonary hypertension
- Periodontal disease
- Heart disease
- Coronary artery bypass graft failure
- Asthma
- Duchenne muscular dystrophy
- Metabolic syndrome
- Non-alcoholic fatty liver disease
- Optic neuropathy




Sales & Marketing: Driving New Growth



Licensing Agreement:


➤ Japan: Nutranomics

- Nutranomics: Leading US-based distributor into Japan; veteran of successful product launches in Asian market
 - Manufacture & MLM with in-country strategic partner
 - Manufacture product to precise Protandim® standards
 - Push product under their brand name in Japan through distributors
 - Also sell direct through Japanese retail channels



Direct Response Marketing

- ▶ June 2005: 6-Minute Piece on Protandim® Aired on Primetime Live
 - Resulted in large sales volume, despite no direct call to action to customer



Direct-Response Commercials

- ▶ Directed by award-winning Peter Baloff
- ▶ Expectation: Direct Response with strong call to action will drive large sales volume at low customer acquisition costs.





Retail Channel: Optimize & Expand


- Existing Channels:
 - Strong avenues in place (GNC, Vitamin Cottage, Others)
 - Increase in-store promotion and education
- New Channels:
 - New CEO has strong contacts at major retailers
 - Goal: Market penetration into major health food retailers

SuperSupplements



Aggressive Online Strategy:

- Web Initiatives:
 - Increased web traffic through affiliates & SEO
 - Change look & appeal of website for increased conversion



Market Comparable:

- ▶ Sirtris Pharmaceuticals (NASDAQ: **SIRT**)
 - \$330 Million Market Cap
 - R&D Stage Company
 - Resveratrol-based antioxidant solution

- ▶ LifeVantage (OTCBB: **LFVN**)
 - Aggressive & Experienced New Management
 - Patents & Clinical Data
 - Historical Revenue & High Growth Strategy
 - \$7 Million Market Cap

LIFEVANTAGE

LIFEVANTAGE


www.LifeVantage.com

LFVN.OB

Marc Blakely, Investor Relations

303.520.6379

Marc@BolderVenture.com



www.LifeVantage.com
www.Protandim.com
OTCBB: LFN

CORPORATE OFFICES:
LifeVantage Corporation
6400 S. Fiddler's Green Circle
Suite 1970
Greenwood Village, CO 80121
☎ 720-488-1711
☎ 720-488-1722

INVESTOR CONTACT:
Marc Blakely
Bolder Venture Partners
☎ 303-520-6379
✉ marc@bolderventure.com

FINANCIAL DATA*

Stock Price**	\$0.30
52 Week High:	\$0.43
52 Week Low	\$0.16
Shares Outstanding***	22.4
3 Month Average Daily Shares Traded***	57,950
Market Cap*	\$6.71M
Cash, Cash Equivalents and Marketable Securities***	\$1.62
Long-Term Debt***	\$0.221
Book Value/Share***	\$0.161

*All numbers in millions except Stock Price, Book Value, and Average Daily Shares Traded.
**As of March 3, 2008
*** As of December 31, 2007

COMPANY OVERVIEW

About LifeVantage: LifeVantage develops innovative, patented dietary supplements that fight the *progressive trend of aging*. The Company's flagship product, **Protandim®**, combats oxidative stress through increasing the body's natural antioxidant protection.

Protandim®: the Only Supplement Clinically Proven to Slow Down the Cell Aging Process.¹

INVESTMENT HIGHLIGHTS

- ✿ Achieved positive cash flow from operations for the first time since 2005
- ✿ New Licensing Agreement, February 2008: Marketing and licensing agreement signed with NutraNomics for the representation and distribution of Protandim into multi-billion dollar Asian market.
- ✿ New CEO/President: Accomplished Industry Veteran David Brown hired in January 2008.
- ✿ New Patent: Granted for Protandim formula by the U.S. Patent and Trademark Office in July 2007



NEW CEO

- ✿ Industry Veteran David Brown
- ✿ Joined LifeVantage on January, 2008
- ✿ Former President/CEO, Metabolife
- Led aggressive transition into key retail channels
- ✿ Former President, Natural Balance, Inc.
- Achieved 300% growth in sales during tenure

	FY 07	FY 08 Q2
Sales	\$ 5.05	\$ 0.80
Cost of Goods	\$ 1.02	\$ 0.19
Total Expenses	\$ 7.72	\$ 1.01
Net Income	\$ (3.69)	\$ (0.40)
EPS	(\$0.17)	\$ (0.02)

* In Millions Except for Per Share Data
** Fiscal Year 2007 ended June 30th, 2007
** Q2 Fiscal Year 2008 ended December 31st, 2007

BOARD OF DIRECTORS

- ✿ James D. Crapo, Ph.D., Chairman: 30 years experience in health and medical field
- ✿ David Brown, President and CEO: Former President and CEO, Metabolife and Natural Balance, Inc.
- ✿ Joe M. McCord, Ph.D.: Co-discovered Superoxide Dismutase (SOD) in 1969
- ✿ Mr. Jack R. Thompson: Director, Sparx Asia Funds and Russell Funds

¹ These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Media Coverage:

Protandim was featured on Primetime Live.

Endorsed on the Today Show by renowned dietician Elizabeth Somer.

Featured in Dr. Sanjay Gupta's book, "Chasing Life".

Market Size:

Over \$100 Billion Spent Annually on Anti-Aging

- ❖ Anti-aging supplements (about \$5 Billion)
- ❖ Anti-aging services and related products (about \$50 Billion)
- ❖ Other cosmetic products such as make-up (about \$50 Billion)
- ❖ Exercise equipment (about \$5 Billion)

Distribution Outlets:

Protandim is available at www.Protandim.com and at leading retail outlets including GNC, Super Supplements, Vitamin Cottage, and Vitamin Shoppe.

Forward Looking Statement: Statements in this document which are not statements of historical fact are "forward-looking statements" within the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on information available to, and the expectations and assumptions deemed reasonable by Lifeline Therapeutics, Inc. and LifeVantage Corporation (the "Company") at the time this document was made. Although the Company believes that the assumptions underlying such statements are reasonable, it can give no assurance that they will be attained. Factors that could cause actual results to differ materially from expectations include the risks detailed under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-KSB, and risks identified in the Company's quarterly reports on Form 10-QSB and in other materials filed by the Company from time to time with the Securities and Exchange Commission.

PRODUCT OVERVIEW

Protandim combats the aging process by fighting the onset of free radicals and the toxins they produce at the cellular level. In a clinical study (shown to the right), subjects who took Protandim for 30 days showed oxidative stress levels decreased to that of a 20 year old.

GROWTH PLANS

- ❖ **Direct Marketing:** Aggressive direct response marketing through television infomercials by award-winning creative director Peter Baloff.
- ❖ **Increased Retail Distribution:** Concentrated growth within existing channels (GNC, Vitamin Shoppe, others); expansion into new organic market channels.
- ❖ **Integrated Online Presence:** Search engine optimization & affiliate growth

R&D: OUR COMPETITIVE ADVANTAGE

Over 20 independent human clinical and lab studies are underway at leading institutions, including the University of Colorado's Health Sciences Center and Ohio State University. One promising study, for example, is investigating the benefits of various antioxidant treatments, including Protandim, on preventing oxidative stress that is thought to stimulate intimal hyperplasia —the thickening of blood vessels as a complication of reconstructive heart procedure. Studies are underway at:

- ❖ University of Colorado
- ❖ University of Florida
- ❖ University of Kentucky
- ❖ Denver Health Medical Center
- ❖ Vanderbilt University
- ❖ University of Michigan
- ❖ Louisiana State University

Topics under investigation include:

- ❖ Skin cancer
- ❖ Renal failure
- ❖ Heart disease
- ❖ Coronary artery bypass graft failure
- ❖ Asthma
- ❖ Duchenne muscular dystrophy
- ❖ Metabolic syndrome
- ❖ Non-alcoholic fatty liver disease
- ❖ Optic neuropathy
- ❖ Pulmonary hypertension



Protandim is a registered trademark of LifeVantage Corporation ©2008. LifeVantage Health is a trademark of LifeVantage Corporation ©2008.

CLINICAL STUDY RESULTS

Inhibition of lipid peroxidation (TBARS) by Protandim®



LifeVantage 3-Month Daily Closing Stock Price (LFVN.OB)

